Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 275 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Dr Ian Walker on Smoking: ‘A political no-brainer’ March 24, 2023 Sacituzumab Govitecan Demonstrates Significant Improvement in PFS in Heavily Pretreated, Locally... September 5, 2022 FDA Grants Accelerated Approval to Pembrolizumab for HER2-positive Gastric Cancer May 10, 2021 Making a startup out of a scientist April 26, 2023 Load more HOT NEWS Reduction Not Only in Recurrences, but Also in Mortality, Observed for... Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC... EMA Recommends Granting a Marketing Authorisation for Equidacent After a Generous Donor Covered Her Bills, Breast Cancer Survivor Raises...
